Clinical Trials · NCT00299871
Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Sanofi
- Enrollment
- 542
- Start date
- Feb 2006
- Locations
- 7 sites, 7 countries
- Primary endpoint
- HbA1c levels at baseline and endpoint (at 13 weeks).